130 related articles for article (PubMed ID: 32929823)
1. Future needs of young people receiving botulinum toxin A in paediatric rehabilitation services of New South Wales: focus on transition.
Paget SP; de Groot A; Hanns K; Burnett H; Ho J
Intern Med J; 2020 Sep; 50(9):1138-1141. PubMed ID: 32929823
[TBL] [Abstract][Full Text] [Related]
2. Development of an inventory of goals using the International Classification of Functioning, Disability and Health in a population of non-ambulatory children and adolescents with cerebral palsy treated with botulinum toxin A.
Nguyen L; Mesterman R; Gorter JW
BMC Pediatr; 2018 Jan; 18(1):1. PubMed ID: 29301539
[TBL] [Abstract][Full Text] [Related]
3. Codesigning a social prescribing pathway to address the social determinant of health concerns of children with cerebral palsy and their families in Australia: a protocol for a mixed-methods formative research study.
Ostojic K; Paget S; Martin T; Dee-Price BJ; McIntyre S; Smithers Sheedy H; Mimmo L; Burnett H; Scott T; Berg A; Masi A; Scarcella M; Calderan J; Azmatullah S; Mohamed M; Woodbury M; Wilkinson A; Zwi K; Dale R; Eapen V; Lingam R; Strnadová I; Woolfenden S;
BMJ Open; 2023 Apr; 13(4):e066346. PubMed ID: 37024248
[TBL] [Abstract][Full Text] [Related]
4. Effects of Botulinum Toxin Treatment in Nonambulatory Children and Adolescents With Cerebral Palsy: Understanding Parents' Perspectives.
Nguyen L; Di Rezze B; Mesterman R; Rosenbaum P; Gorter JW
J Child Neurol; 2018 Oct; 33(11):724-733. PubMed ID: 30039731
[TBL] [Abstract][Full Text] [Related]
5. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy.
O'Flaherty SJ; Janakan V; Morrow AM; Scheinberg AM; Waugh MC
Dev Med Child Neurol; 2011 Feb; 53(2):125-30. PubMed ID: 21244412
[TBL] [Abstract][Full Text] [Related]
6. Treatment with botulinum toxin in children with cerebral palsy: a qualitative study of parents' experiences.
Lorin K; Forsberg A
Child Care Health Dev; 2016 Jul; 42(4):494-503. PubMed ID: 27198886
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.
Flett PJ; Stern LM; Waddy H; Connell TM; Seeger JD; Gibson SK
J Paediatr Child Health; 1999 Feb; 35(1):71-7. PubMed ID: 10234640
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular Botulinum toxin-A injections.
Read FA; Boyd RN; Barber LA
Res Dev Disabil; 2017 Sep; 68():35-41. PubMed ID: 28735160
[TBL] [Abstract][Full Text] [Related]
9. Use of botulinum toxin A in children with cerebral palsy.
Ross Raftemo AE; Mahendran A; Hollung SJ; Jahnsen RB; Lydersen S; Vik T; Andersen GL
Tidsskr Nor Laegeforen; 2019 May; 139(8):. PubMed ID: 31062563
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of a Propofol and Ketamine Based Procedural Sedation Protocol in Children with Cerebral Palsy Undergoing Botulinum Toxin A Injections.
Louer R; McKinney RC; Abu-Sultaneh S; Lutfi R; Abulebda K
PM R; 2019 Dec; 11(12):1320-1325. PubMed ID: 30761757
[TBL] [Abstract][Full Text] [Related]
11. Transition from paediatric to adult health services in Scotland for young people with cerebral palsy.
Wright AE; Robb J; Shearer MC
J Child Health Care; 2016 Jun; 20(2):205-13. PubMed ID: 25593215
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation for spasticity of calf muscle after botulinum toxin injection in patients with cerebral palsy: a pilot study.
Lin YC; Lin IL; Chou TF; Lee HM
J Neuroeng Rehabil; 2016 Mar; 13():25. PubMed ID: 26969526
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of infants born at less than 28 weeks' gestation in New South Wales, Australia, in 1992-3. New South Wales Neonatal Intensive Care Unit Study Group.
Sutton L; Bajuk B
Paediatr Perinat Epidemiol; 1999 Jul; 13(3):288-301. PubMed ID: 10440049
[TBL] [Abstract][Full Text] [Related]
14. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
[TBL] [Abstract][Full Text] [Related]
15. Experience with botulinum toxin in the treatment of cerebral palsy.
Arens LJ; Leary PM; Goldschmidt RB
S Afr Med J; 1997 Aug; 87(8):1001-3. PubMed ID: 9323408
[TBL] [Abstract][Full Text] [Related]
16. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
[TBL] [Abstract][Full Text] [Related]
17. The influence of physical therapy and anti-botulinum toxin antibody on the efficacy of botulinum toxin-A injections in children with spastic cerebral palsy.
Jang DH; Sung IY
Dev Neurorehabil; 2014 Dec; 17(6):414-9. PubMed ID: 25372070
[TBL] [Abstract][Full Text] [Related]
18. Genomic Epidemiology of Clostridium botulinum Isolates from Temporally Related Cases of Infant Botulism in New South Wales, Australia.
McCallum N; Gray TJ; Wang Q; Ng J; Hicks L; Nguyen T; Yuen M; Hill-Cawthorne GA; Sintchenko V
J Clin Microbiol; 2015 Sep; 53(9):2846-53. PubMed ID: 26109442
[TBL] [Abstract][Full Text] [Related]
19. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review.
Gormley ME; Gaebler-Spira D; Delgado MR
J Child Neurol; 2001 Feb; 16(2):113-8. PubMed ID: 11292216
[TBL] [Abstract][Full Text] [Related]
20. Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy.
Büyükavcı R; Büyükavcı MA
Acta Neurol Belg; 2018 Sep; 118(3):429-433. PubMed ID: 29694645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
